Next Article in Journal
Education Intervention on Chronotherapy for Final-Year Pharmacy Students
Previous Article in Journal
Use of Etomidate for Rapid Sequence Intubation (RSI) in Pediatric Trauma Patients: An Exploratory National Survey
Open AccessReview

Posaconazole: An Update of Its Clinical Use

1
Memorial Regional Hospital, Hollywood, FL 33021, USA
2
Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL 33416
3
Boca Raton Regional Hospital, Boca Raton, FL 33486, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Yvonne Perrie
Pharmacy 2015, 3(4), 210-268; https://doi.org/10.3390/pharmacy3040210
Received: 1 May 2015 / Revised: 11 August 2015 / Accepted: 26 August 2015 / Published: 21 October 2015
Posaconazole (PCZ) is a relatively new addition to the azole antifungals. It has fungicidal activities against Aspergillus fumigatus, Blastomyces dermatitidis, selected Candida species, Crytopcoccus neoformans, and Trichosporon. PCZ also has fungistatic activities against Candida, Coccidioides, selected Fusarium spp., Histoplasma, Scedosporium and Zygomycetes. In addition, combining the drug with caspofungin or amphotericin B results in a synergistic interaction against A. fumigatus, C. glabrata and C. neoformans. The absorption of PCZ suspension is enhanced when given with food, nutritional supplements, and carbonated beverages. Oral administration of PCZ in divided doses also increases its bioavailability. PCZ has a large volume of distribution and is highly protein bound (>95%). The main elimination route of PCZ is fecal. PCZ is an inhibitor of the CYP3A4 enzyme; therefore, monitoring for drug-drug interactions is warranted with other CYP3A4 substrates/inhibitors/inducers. The most common adverse effects include headache, fatigue, nausea, vomiting and elevated hepatic enzymes. PCZ, with its unique antifungal activities, expands the azole class of antifungal agents. Because of its limit in formulation, PCZ oral suspension is recommended in immunocompromised patients with functional gastrointestinaltracts who fail conventional antifungal therapies or who are suspected to have a breakthrough fungal infection. However, a delayed-release tablet formulation and intravenous (IV) injection became available in 2014, expanding the use of PCZ in other patient populations, including individuals who are unable to take oral formulations. View Full-Text
Keywords: posaconazole; pharmacokinetics; pharmacodynamics; crytococcus neoformans; Candida; aspergillus; fusariosi; neutropenia; candidiasis; graft-versus-host posaconazole; pharmacokinetics; pharmacodynamics; crytococcus neoformans; Candida; aspergillus; fusariosi; neutropenia; candidiasis; graft-versus-host
Show Figures

Figure 1

MDPI and ACS Style

Leung, S.; Poulakos, M.N.; Machin, J. Posaconazole: An Update of Its Clinical Use. Pharmacy 2015, 3, 210-268.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop